Mohammad, AnjoomChand, Miyan KamaalBeg, Mirza AtifBawa, Shalu2020-09-242020-09-242019-09Mohammad Anjoom, Chand Miyan Kamaal, Beg Mirza Atif, Bawa Shalu. Comparative Evaluation of DPP-IV Inhibitors and other Oral Hypoglycaemic Agents used Either Alone or in Combination with Reference to Glycemic Targets in Patients with Type 2 Diabetes Mellitus. International Journal of Contemporary Medical Research . 2019 Sep; 6(9): i5-i112393-915X2454-7379http://imsear.searo.who.int/handle/123456789/202549Introduction: This study assumes significance as it compareshead on DPP-IV inhibitors along with other oral hypoglycemicagents with respect to glycemic and non-glycemic targets.Study was done to evaluate the DPP-IV inhibitors andother oral hypoglycemic agents (OHA) either alone or incombination, with reference to glycemic targets like fastingplasma glucose (FPG), post prandial glucose (PPG) andglycosylated hemoglobin (HbA1c) in type 2 diabetes mellitus.Material and Methods: This was an open labelledcomparative study and included 90 patients with Type 2 DM.These patients were divided into 3groups: Each group wascontaining 30 patients i.e. Group A: DPP-IV inhibitors (n=30); Group B: Oral hypoglycemic agents other than DPP-IVinhibitors (n= 30) and Group C: DPP-IV inhibitors + other oralhypoglycemic agents (n= 30). The patients were given drugson the basis of physician’s discretion, depending upon theglycemic of the patients at the time of presentation. A detailedhistory regarding age, sex, profession, duration of disease,treatment history, family history and personal history wastaken for each patient. After stabilization patients observed at0 weeks, 6 weeks, 12 weeks and 24 weeks.Results: Mean duration of diabetes was 5.35±0.53 years, andthe mean age of onset of diabetes was 46.98±0.91years. Therewas no significant difference between the study groups withrespect to FPG, PPG, and HbA1c levels. The HbA1c showedsignificant improvement in each group at the end of studyperiod.Conclusion: In summary, this study showed that treatmentwith sitagliptin, either alone or in combination with other oralhypoglycemic agent led to clinically meaningful reductionsin HbA1c, FPG and PPG over a 24 week period. Sitagliptinpresents an alternative therapeutic strategy for patientswith type 2 diabetes and, in general, showed significantimprovements in glycemic control and is well tolerated,particularly with regard to weight change and hypoglycemia.Diabetes MellitusOral Hypoglycemic AgentsPP-IV InhibitorsGlycaemic ControlGlycosylated hemoglobinJournal ArticleIndiaAssistant Professor, Department of Pharmacology and Therapeutics, Shaikh-Ul-Hind Maulana Mahmood Hasan Medical College, Saharanpur, Uttar PradeshAssociate Professor, Department of Pharmacology and Therapeutics, Shaikh-Ul-Hind Maulana Mahmood Hasan Medical College, Saharanpur, Uttar PradeshProfessor, Department of Pharmacology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun UttarakhandAssociate Professor, Department of Pharmacology, Shri Guru Ram Rai Institute of Medical and Health Sciences, Dehradun, Uttarakhand, India